Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mokelumne river who wrote (1387)	7/27/2015 9:53:55 AM
From: eico20	Read Replies (2) of 2026

Good news for Mylan, Teva drops takeover bid, maybe Vitraos can get back on track now in Canada Teva Pharmaceutical (NYSE: TEVA) confirmed reports Monday that it will buy Allergan's (NYSE: AGN) generic drugs business for $40.5 billion and dropped its hostile takeover bid for Mylan Pharmaceuticals (NASDAQ: MYL). Under the deal, Teva will pay $33.75 billion in cash and $6.75 billion in shares. The deal is expected to close in Q1 2016. With the hostile bid for Mylan over, Mylan said it would continue pursuing Perrigo (NYSE: PRGO). Mylan shareholders will vote on the acquisition in the "next several weeks," according to the company. Perrigo shares rallied 3% premarket

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next